US20090062377A1 - Anti-cancer combinations - Google Patents
Anti-cancer combinations Download PDFInfo
- Publication number
- US20090062377A1 US20090062377A1 US12/264,197 US26419708A US2009062377A1 US 20090062377 A1 US20090062377 A1 US 20090062377A1 US 26419708 A US26419708 A US 26419708A US 2009062377 A1 US2009062377 A1 US 2009062377A1
- Authority
- US
- United States
- Prior art keywords
- compound
- formula
- nsaid
- radical
- dmxaa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 [1*]C.[2*]C.[4*]/C1=C(\[5*])OC2=CC=CC=C2C1=O Chemical compound [1*]C.[2*]C.[4*]/C1=C(\[5*])OC2=CC=CC=C2C1=O 0.000 description 13
- XGOYIMQSIKSOBS-UHFFFAOYSA-N CC1=CC=C2C(=O)C3=C(OC2=C1C)C(CC(=O)O)=CC=C3 Chemical compound CC1=CC=C2C(=O)C3=C(OC2=C1C)C(CC(=O)O)=CC=C3 XGOYIMQSIKSOBS-UHFFFAOYSA-N 0.000 description 1
- VQFRXBNJEUCQQA-UHFFFAOYSA-N OC(Bc(cccc12)c1Oc(cccc1)c1C2=O)=O Chemical compound OC(Bc(cccc12)c1Oc(cccc1)c1C2=O)=O VQFRXBNJEUCQQA-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to synergistic combinations of the compounds of formula I such as compounds of the xanthenone acetic acid class such as 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and NSAIDs, in particular diclofenac, which have anti-tumour activity. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing said combinations.
Description
- This application is a Continuation-In-Part of PCT/GB03/01320, filed Mar. 20, 2003, which published in English and designated the U.S., and which claimed the priority of Great Britain patent application No. GB 0206839.3, filed Mar. 22, 2002, the entirety of each of which is hereby incorporated by reference.
- The present invention relates to synergistic combinations of the compounds of the class having the formula (I) as defined below, for example compounds of the xanthenone acetic acid class having the formula (II) as defined below, such as 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and non-steroidal anti-inflammatory drugs such as cyclo-oxygenase inhibitors, in particular diclofenac, which have anti-tumour activity. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing such combinations.
- 5,6-dimethylxanthenone-4-acetic acid (DMXAA) is represented by the following formula:
- Phase I clinical trials of DMXAA have recently been completed, with dynamic MRI showing that it induces a significant reduction in tumour blood flow at well-tolerated doses. DMXAA is thus one of the first antivascular agents for which activity (irreversible inhibition of tumour blood flow) has been documented in human tumours. These findings are in agreement with preclinical studies using tumours or human tumour xenografts which showed that its antivascular activity produced prolonged inhibition of tumour blood flow leading to extensive regions of haemorrhagic necrosis.
- Non-steroidal anti-inflammatory drugs (NSAIDs) share the capacity to suppress the signs and symptoms of inflammation. Many also exert antipyretic and analgesic effects.
- Salicylate is the major anti-inflammatory metabolite of aspirin, the original NSAID. Aspirin irreversibly acetylates and blocks platelet cyclooxygenase. Other NSAIDS are reversible inhibitors. Selectivity for COX-1 and COX-2 is variable for many of the traditional NSAIDs. Ibuprofen inhibits COX-2 and COX-1 to approximately the same extent. However, highly selective COX-2 inhibitors (celecoxib and rofecoxib) are now available.
- Diclofenac is a non-steroidal anti-inflammatory drug (NSAID) having the chemical name 2-[(2,6-dichlorophenyl)amino]benzeneacetic acid. Diclofenac potassium is available as Cataflam® with Diclofenac sodium available as VOLTAREN®. Diclofenac is indicated for the acute and chronic treatment of signs and symptoms of osteoarthritis and rheumatoid arthritis and treatment of ankylosing spondylitis, analgesia and primary dysmennorrhea.
- Pharmacokinetic drug interaction is defined as one where drug A affects the plasma (or tissue) concentration of drug B, by altering the latter's absorption, distribution, excretion or metabolism (Dorr and Fritz, Cancer Chemotherapy Handbook, Henry Kimpton Publishers, London. 1980; Tenenbaum, L., Cancer chemotherapy—a Reference Guide, W.B. Saunders, New York. 1989). The combination therapy of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and thalidomide is one of the examples of pharmacokinetic interactions that involve alteration in drug metabolism.
- UGT 1A9, UGT 2B7, and CYP 1A2 have been shown to be involved in the metabolism of DMXAA (Miners et al Cancer Res., 57: 284-289, 1997; Zhou et al J. Chromatog. B, 757: 343-348, 2001). Glucuronidation is the major metabolic elimination pathway of DMXAA (Miners et al Cancer Res., 57: 284-289, 1997; Kestell et al, Cancer Chemother. Pharmacol., 46: 135-141, 2000). DMXAA can also be metabolized by 6-methylhydroxylation, but to a lesser extent (Zhou et al J. Chromatog. B, 757: 343-348, 2001). The product of glucuronidation, DMXAA acyl glucuronide (DMXAA-G), and the product of 6-methylhydroxylation, 6-methylhydroxyl-5-methylxanthenone-4-acetic acid (6-OH— MXAA), are then excreted in bile and urine (Zhou et al J. Chromatog. B, 757: 343-348, 2001).
- Diclofenac has been shown to affect the metabolism of DMXAA. At a concentration of 100 μM, diclofenac has been shown to significantly inhibit glucoronidation (>70%) and 6-methylhydroxylation (>54%) of DMXAA in mouse and human microsomes. In vivo, diclofenac (100 mg/kg i.p.) has been shown to result in a 24% and 31% increase in the plasma DMXAA AUC (area under the plasma concentration-time curve) and a threefold increase in T1/2 (P<0.05) in male and female mice respectively (Zhou et al (2001) Cancer Chemother Pharmacol 47 319-326).
- It has now surprisingly been found that by administering, either concomitantly or sequentially, compounds having the formula (I) as defined below with an NSAID such as the NSAID diclofenac at NSAID concentrations which do not affect the plasma pharmacokinetics of compounds of formula (I), potentiation of the antitumour activity of compounds formula (I) as defined above is nevertheless achieved.
- In particular co-administration of compounds of formula (I) as defined below such as DMXAA with NSAIDS such as diclofenac provides a therapeutic gain against sub-cutaneously established (3-5 mm, approximately 20 mg) colon 38 tumour fragments at concentrations of NSAID which does not significantly affect the plasma pharmacokinetics of the compound of formula (I) as defined below.
- Thus, in a first aspect, the present invention provides a method for modulating neoplastic growth, which comprises administering to a mammal, including a human, in need of treatment an effective amount of a compound of the formula (I):
- or a pharmaceutically acceptable salt or ester thereof and concomitantly or sequentially administering an effective amount of a NSAID, wherein said effective amount of said NSAID is less than that required to substantially alter the plasma pharmacokinetics of the compound of the xanthenone acetic acid class having the formula (I) as defined above in said mammal;
wherein: - (a) R4 and R5 together with the carbon atoms to which they are joined, form a 6-membered aromatic ring having a substituent —R3 and a radical —B)—COOH where B is a linear or branched substituted or unsubstituted C1-C6 alkyl radical, which is saturated or ethylenically unsaturated, and wherein R1, R2 and R3 are each independently selected from the group consisting of H, C1-C6 alkyl, halogen, CF3, CN, NO2, NH2, OH, OR, NHCOR, NHSO2R, SR, SO2R or NHR, wherein each R is independently C1-C6 alkyl optionally substituted with one or more substituents selected from hydroxy, amino and methoxy; or
- (b) one of R4 and R5 is H or a phenyl radical, and the other of R4 and R5 is H or a phenyl radical which may optionally be substituted, thenyl, furyl, naphthyl, a C1-C6 alkyl, cycloalkyl, or aralkyl radical; R1 is H or a C1-C6 alkyl or C1-C6 alkoxy radical; R2 is the radical —(B)—COOH where B is a linear or branched substituted or unsubstituted C1-C6 alkyl radical, which is saturated or ethylenically unsaturated.
- Where the radical —(B)—COOH is a substituted C1-C6 alkyl radical, the substituents may be alkyl, for example methyl, ethyl, propyl or isopropyl, or halide such as fluoro, chloro or bromo groups. A particularly preferred substituent is methyl.
- In one embodiment of the first aspect of the invention, the compound of the formula (I) as defined above is a compound of the formula (II),
- where R1, R4, R5 and B are as defined above for formula (I) in part (b).
- In a preferred embodiment of the first aspect of the invention, the compound of formula (I) as defined above is a compound of the formula (III)
- wherein R1, R2 and R3 are each independently selected from the group consisting of H, C1-C6 alkyl, halogen, CF3, CN, NO2, NH2, OH, OR, NHCOR, NHSO2R, SR, SO2R or NHR, wherein each R is independently C1-C6 alkyl optionally substituted with one or more substituents selected from hydroxy, amino and methoxy;
wherein B is as defined for formula (I) above;
and wherein in each of the carbocyclic aromatic rings in formula (I), up to two of the methine (—CH═) groups may be replaced by an aza (—N═) group;
and wherein any two of R1, R2 and R3 may additionally together represent the group —CH═CH—CH═CH—, such that this group, together with the carbon or nitrogen atoms to which it is attached, forms a fused 6 membered aromatic ring. - Preferably, the compound of formula (III) is a compound of the formula (IV):
- wherein R, R1, R2 and R3 are as defined for formula (III).
- In a preferred embodiment of the compound of formula (IV), R2 is H, one of R1 and R3 is selected from the group consisting of C1-C6 alkyl, halogen, CF3, CN, NO2, NH2, OH, OR, NHCOR, NHSO2R, SR, SO2R or NHR, wherein each R is independently C1-C6 alkyl optionally substituted with one or more substituents selected from hydroxy, amino and methoxy, and the other of R1 and R3 is H.
- Preferably, the compound of formula (IV) is of the formula (V):
- wherein R, R1, R2 and R3 are as defined for formula IV.
- Most preferably, the compound of formula (IV) is 5,6-
dimethylxanthenone 4 acetic acid (DMXAA). - In the context of the present invention, a concentration of NSAID is considered not to substantially alter the plasma pharmacokinetics of the compound of formula (I) as defined above in the mammal if the plasma concentration of the compound of formula (I) in the mammal is not significantly increased (P<0.05), as judged by the compound of formula (I) AUC (area under the plasma concentration-time curve) and/or T1/2 of the compound of formula (I) in plasma. Preferably neither the AUC nor the T1/2 values are significantly different between mammals treated with the compound of formula (I) monotherapy and those treated with the compound of formula (I) and the NSAID. An alternative or preferably additional test to assess whether or not a concentration of NSAID may be considered in the context of the present invention to not substantially alter the plasma pharmacokinetics of a compound of formula (I) in a mammal may be measurement of metabolites. For example, where the compound of formula (I) is DMXAA, concentration of metabolites such as DMXAA acyl glucoronide (DMXAA-G) and 6-methylhydroxyl-5-methylxanthenone-4-acetic acid (6-OH-MXAA) may be measured. A concentration of NSAID may be considered to not substantially alter the plasma pharmacokinetics of DMXAA in a mammal if the NSAID does not cause significant inhibition of glucoronidation or 6-methylhydroxylation of DMXAA as assessed by measurement of DMXAA-G or 6-OH-MXAA concentration in an assay of DMXAA metabolism in the presence and absence of the NSAID. Suitable in vitro and in vivo assays are known to the skilled person. For example, an in vitro assay based on liver microsomal preparations which may be used to assess DMXAA metabolism is described in Zhou et al (2001) Cancer Chemother Pharmacol 47 319-326. More suitably, an High Performance Liquid Chromatography (HPLC) based method may be used to measure suitable HPLC based assay may be used to measure the concentrations of NSAID metabolites in the plasma or urine of a subject. Such an assay is described in Kestell, P et al (1999): Cancer Chemother. Pharmacol. 43, 323-330, the contents of which is hereby incorporated by reference.
- In another aspect, the present invention provides the use of a compound of formula (I) as defined above or a pharmaceutically acceptable salt or ester thereof for the manufacture of a medicament, for administration either concomitantly or sequentially with a unit dose of a cyclooxygenase inhibitor compound, for the modulation of neoplastic growth, wherein said unit dose comprises said NSAID compound in an amount which is less than that required to substantially alter the plasma pharmacokinetics of the compound of formula (I) in the mammal.
- In a further aspect, the present invention provides the use of a NSAID compound for the manufacture of a unit dose of a medicament, for simultaneous, separate or sequential administration with a compound of formula (I) as defined above or a pharmaceutically acceptable salt or ester thereof, for the modulation of neoplastic growth, wherein said unit dose comprises said NSAID compound in an amount which is less than that required to substantially alter the plasma pharmacokinetics of DMXAA in a subject to be treated.
- In a still further aspect, the present invention provides a combined preparation of a compound of formula (I) as defined above or a pharmaceutically acceptable salt or ester thereof and a NSAID compound for simultaneous, separate or sequential use, e.g. for modulation of neoplastic growth, wherein the compound of formula (I) or pharmaceutically acceptable salt or ester thereof and the NSAID compound are present in a potentiating ratio, and wherein said NSAID compound is present in an amount which is less than that required to substantially alter the plasma pharmacokinetics of the compound of formula (I) in a subject to which the combination is administered.
- In a further aspect, there is provided a pharmaceutical formulation comprising a combination of a compound of formula (I) as defined above or a pharmaceutically acceptable salt or ester thereof and a NSAID compound wherein a unit dose of said pharmaceutical formulation comprises said NSAID compound in an amount which is less than that required to substantially alter the plasma pharmacokinetics of a compound of formula (I) as defined above in a subject to be treated.
- The invention further provides a process for the preparation of a pharmaceutical formulation which process comprises bringing into association a combination of a compound of formula (I) as defined above or a pharmaceutically acceptable salt or ester thereof and a NSAID compound with one or more pharmaceutically acceptable carriers therefor in a unit dose in which said NSAID compound is in an amount which is less than that required to substantially alter the plasma pharmacokinetics of the compound of formula (I) in a subject to be treated.
- Furthermore, the invention also provides a kit comprising in combination for simultaneous, separate or sequential use in modulating neoplastic growth, a compound of formula (I) as defined above or a pharmaceutically acceptable salt or ester thereof and a NSAID compound, wherein said NSAID is provided in a unit dose comprising an amount of NSAID which is less than that required to substantially alter the plasma pharmacokinetics of the compound of formula (I) in a subject to be treated.
-
FIG. 1 . shows growth of colon 38 tumours untreated (circle), or following treatment with DMXAA (25 mg/kg, triangle), diclofenac (5 mg/kg, diamond) or the combination (DMXAA (25 mg/kg) and diclofenac (5 mg/kg, square). Mean±SEM (standard error of the mean) of 5 mice per group. -
FIG. 2 shows the time course of DMXAA plasma concentration following treatment with DMXAA (25 mg/kg, circle), or the combination (DMXAA (25 mg/kg) and diclofenac (5 mg/kg, triangle). Mean±SEM of 3 mice per time point. -
FIG. 3 shows the time course of DMXAA intratumoural concentration following treatment with DMXAA (25 mg/kg, circle), or the combination (DMXAA (25 mg/kg) and diclofenac (5 mg/kg, triangle). Mean±SEM of 3 mice per time point. - In one embodiment the NSAID compound is a cylooxygenase inhibitor. Preferably the NSAID is a COX-2 inhibitor. In preferred embodiments of the invention, the NSAID is selected from the group comprising diclofenac, salicylate, ibuprofen, sulindac celecoxib and rofecoxib. In a particularly preferred embodiment, the NSAID is diclofenac.
- The term ‘potentiating ratio’ is used herein to indicate that the compound of formula (I) as defined above or pharmaceutically acceptable salt or ester thereof and the NSAID compound are present in a ratio such that the antitumour activity of the combination is greater than that of either the compound of formula (I) or the NSAID compound alone or of the additive activity that would be predicted for the combinations based on the activities of the individual components. Thus the individual components act synergistically in combination provided they are present in a potentiating ratio.
- The compound of formula (I) as defined above or pharmaceutically acceptable salt or ester thereof and the NSAID compound may be administered simultaneously, separately or sequentially. Preferably the compound of formula (I) as defined above or pharmaceutically acceptable salt or ester thereof and the NSAID compound are administered within 6 hours, more preferably 4 hours, more preferably 2 hours of one another. Most preferably the compound of formula (I) as defined above or pharmaceutically acceptable salt or ester thereof and the NSAID compound are administered simultaneously. For example the two drugs may be administered simultaneously by infusion over 0.2 to 6 hours, for example 0.33 to 3 hours.
- Preferably the compound of formula (I) or pharmaceutically acceptable salt or ester thereof and the NSAID compound are administered in a potentiating ratio. Preferably the pharmaceutically acceptable salt is the sodium salt.
- A potentiating ratio, for a compound of formula (I) as defined above and the NSAID which may be successfully used to treat cancer, is preferably in the range 150:1 to 1:15, more preferably in the range 75:1 to 1:10, even more preferably 50:1 to 1:5, for example 25:1 to 1:1, 15:1 to 1:1. Suitably, the potentiating ratio is in the range 10:1 to 1:1. Most preferred is a potentiating ratio of approximately 5:1.
- As used herein, the term “modulating neoplastic growth” means a change of at least 10% in the rate of neoplastic growth relative to the rate of growth of neoplastic cells in the absence of a compound as described herein. It is preferred that the change be a decrease in neoplastic growth, and further preferred that the change be by at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more, up to and including 100%, or cessation of growth. Modulation of neoplastic growth, as the term is used herein also encompasses regression of neoplasm size, mass or cell number relative to pre-treatment levels.
- The amount of a combination of a compound of formula (I) or formula (II) as defined above, for example DMXAA or a pharmaceutically acceptable salt or ester thereof and the NSAID compound required to be effective as an anticancer agent will, of course, vary and is ultimately at the discretion of the medical practitioner. The factors to be considered include the route of administration and nature of the formulation, the mammal's bodyweight, age and general condition and the nature and severity of the disease to be treated.
- In general, a suitable effective dose of NSAID to be used in combination with DMXAA for administration to man for treatment of cancer may be a dose which is substantially non-toxic to man and which does not substantially affect the pharmacokinetics of DMXAA. A dose of NSAID may be considered to not substantially affect the pharmacokinetics of a compound e.g. DMXAA if, for example, it does not substantially inhibit glucoronidation or 6-methylhydroxylation of that compound, for example it inhibits glucoronidation or 6-methylhydroxylation of that compound by less than 40%, preferably less than 30%, 20%, 15%, 10%, 5%, 2%, most preferably less than 1% or 0.1%.
- In general, a suitable effective dose of a combination of DMXAA and an NSAID for administration to man for treatment of cancer is in the range of 600 to 4900 mg/m2 of DMXAA and 0.01 to 5 mg/kg of an NSAID such as diclofenac. For example from 600 to 4900 mg/m2 of DMXAA and 0.025 to 4 mg/kg of an NSAID such as diclofenac, suitably 1200 to 3500 mg/m2 of DMXAA and 0.05 to 4 mg/kg of NSAID, particularly 2000 to 3000 mg/m2 of DMXAA and 0.1 to 3 mg/kg of NSAID, more particularly 2250 to 2750 mg/m2 of DMXAA and 0.2 to 2.5 mg/kg of NSAID, more particularly 2250 to 2750 mg/m2 of DMXAA and 0.05 to 2 mg/kg of NSAID. A particularly preferred dose is in the range 2250 to 2750 mg/m2 of DMXAA and 0.75 to 1.25 mg/kg mg/m2 of NSAID. A further particularly preferred dose is in the range 2250 to 2750 mg/m2 of DMXAA and 0.1 to 0.5 mg/kg of NSAID, for example 0.1 to 0.25 mg/kg.
- The compound of formula (I), or pharmaceutically acceptable salt or ester thereof and the NSAID compound may be administered in any suitable form. However, for use according to the present invention the combination of a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof and a NSAID compound is preferably presented as a pharmaceutical formulation.
- Pharmaceutical formulations comprise the active ingredients (that is, the combination of compound of formula (I) or a pharmaceutically acceptable salt or ester thereof and a NSAID compound) together with one or more pharmaceutically acceptable carriers therefor and optionally other therapeutic and/or prophylactic ingredients. The carrier(s) must be acceptable in the sense of being compatible with the other ingredients of the formula and not deleterious to the recipient thereof.
- Accordingly, the present invention provides a pharmaceutical formulation comprising a combination of compound of formula (I) or a pharmaceutically acceptable salt or ester thereof and a NSAID compound in association with one or more pharmaceutically acceptable carriers therefor, wherein the NSAID compound is present in an amount which is less than that required to substantially alter the plasma pharmacokinetics of compound of formula (I) in a subject to which the combination is administered.
- The present invention further provides a process for the preparation of a pharmaceutical formulation which process comprises bringing into association a combination of compound of formula (I) or a pharmaceutically acceptable salt or ester thereof and a NSAID compound with one or more pharmaceutically acceptable carriers therefor, wherein said NSAID compound is present in said pharmaceutical formulation in an amount which is less than that required to substantially alter the plasma pharmacokinetics of compound of formula (I) in a subject to which the pharmaceutical formulation is administered.
- Pharmaceutical formulations include those suitable for oral, topical (including dermal, buccal and sublingual), rectal and parenteral (including subcutaneous, intradermal, intramuscular and intravenous) administration as well as administration by naso-gastric tube. The formulation may, where appropriate, be conveniently presented in discrete dosage units and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing into association the active ingredients with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation.
- Preferably the pharmaceutical formulations are adapted for parenteral administration, most preferably intravenous administration. For example the compounds may be administered intravenously using formulations for each compound already known in the art.
- Pharmaceutical formulations suitable for oral administration wherein the carrier is a solid are most preferably presented as unit dose formulations such as boluses, capsules or tablets each containing a predetermined amount of the active ingredients. A tablet may be made by compression or moulding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active compounds in a free-flowing form such as a powder or granules optionally mixed with a binder, lubricant, inert diluent, lubricating agent, surface-active agent or dispersing agent. Moulded tablets may be made by moulding an inert liquid diluent. Tablets may be optionally coated and, if uncoated, may optionally be scored. Capsules may be prepared by filling the active ingredients, either alone or in admixture with one or more accessory ingredients, into the capsule shells and then sealing them in the usual manner. Cachets are analogous to capsules wherein the active ingredients together with any accessory ingredient(s) are sealed in a rice paper envelope. The combination of compound of formula (I) or a pharmaceutically acceptable salt or ester thereof and a NSAID compound may also be formulated as dispersible granules, which may for example be suspended in water before administration, or sprinkled on food. The granules may be packaged e.g. in a sachet. Formulations suitable for oral administration wherein the carrier is a liquid may be presented as a solution or a suspension in an aqueous liquid or a non-aqueous liquid, or as an oil-in-water liquid emulsion.
- Formulations for oral administration include controlled release dosage forms e.g. tablets wherein the active ingredients are formulated in an appropriate release—controlling matrix, or are coated with a suitable release—controlling film. Such formulations may be particularly convenient for prophylactic use.
- The active ingredients may also be formulated as a solution or suspension suitable for administration via a naso-gastric tube.
- Pharmaceutical formulations suitable for rectal administration wherein the carrier is a solid are most preferably presented as unit dose suppositories. Suitable carriers include cocoa butter and other materials commonly used in the art. The suppositories may be conveniently formed by admixture of the active combination with the softened or melted carrier(s) followed by chilling and shaping in moulds.
- Pharmaceutical formulations suitable for parenteral administration include sterile solutions or suspensions of the active combination in aqueous or oleaginous vehicles. Injectible preparations may be adapted for bolus injection or continuous infusion. Such preparations are conveniently presented in unit dose or multi-dose containers which are sealed after introduction of the formulation until required for use. Alternatively, the active ingredients may be in powder form which are constituted with a suitable vehicle, such as sterile, pyrogen-free water, before use.
- The combination of compound of formula (I) or a pharmaceutically acceptable salt or ester thereof and NSAID compound may also be formulated as a long-acting depot preparation, which may be administered by intramuscular injection or by implantation e.g. subcutaneously or intramuscularly. Depot preparations may include, for example, suitable polymeric or hydrophobic materials, or ion-exchange resins. Such long-acting formulations are particularly convenient for prophylactic use.
- It should be understood that in addition to the aforementioned carrier ingredients the pharmaceutical formulations for the various routes of administration described above may include, as appropriate one or more additional carrier ingredients such as diluents, buffers, flavouring agents, binders, surface active agents, thickeners, lubricants, preservatives (including anti-oxidants) and the like, and substances included for the purpose of rendering the formulation isotonic with the blood of the intended recipient.
- Compounds of formula (I) and (II) may be prepared by methods known in the art. For instance, compounds of formula (I), wherein R1, R2, R3, and R4, are as defined in part (b) of the definition of formula (I) as recited above, may be prepared using the methods as disclosed in U.S. Pat. No. 4,602,034 (Briet et al), the contents of which are herein incorporated by reference.
- Compounds of formula (III), (IV) and (V) are known and may be prepared using the methods known in the art. For example, compounds of formula (III), (IV) and (V) and their preparation are described in the following references, the contents of which are herein incorporated by reference:
- Rewcastle et al, Journal of Medicinal Chemistry 34(1): 217-22, January 1991;
- Rewcastle et al, Journal of Medicinal Chemistry 34(2): 491-6, February 1991;
- Atwell et al, Journal of Medicinal Chemistry 33(5): 1375-9, May 1990;
- Rewcastle et al, Journal of Medicinal Chemistry 34(9): 2864-70, September 1991;
- Rewcastle et al, Journal of Medicinal Chemistry 32(4): 793-9, April 1989
- DMXAA may be prepared according to the methods described in Rewcastle et al, Journal of Medicinal Chemistry 34(1): 217-22, January 1991, the contents of which are incorporated herein by reference.
- The NSAIDs may be prepared by any suitable method known to the skilled person. For example, diclofenac is a well known compound and can be prepared by methods known to those skilled in the art.
- The efficacy of treatment as described herein can be determined by one of skill in the art. Treatment is considered effective if neoplastic growth is modulated, as that term is defined herein. Thus, a slowing, halt or regression of neoplastic growth following treatment as described herein is considered effective treatment.
- Examples of cancers that may be treated using methods as described herein include, without limitation, acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemia, acute myeloblastic leukemia, acute promyelocytic leukemia, acute myelomonocytic leukemia, acute monocytic leukemia, acute erythroleukemia, chronic leukemia, chronic myelocytic leukemia, chronic lymphocytic leukemia, polycythemia vera, Hodgkin's disease, non-Hodgkin's disease, Waldenstrom's macroglobulinemia, heavy chain disease, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, lelomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, seminoma, embryonal carcinoma, Wilms tumor, cervical cancer, uterine cancers, testicular cancers, lung carcinoma, small cell lung carcinomas, bladder carcinoma, epithelial carcinom, gliomas, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodenroglioma, schwannoma, meningioma, melanoma, neuroblastoma, and retinoblastoma.
- It is to be understood that the present invention covers all combinations of suitable and preferred groups described hereinabove.
- The present invention will now be illustrated, but is not intended to be limited, by means of the following examples.
- C57B1/6 mice from the Animal Resource Unit, University of Auckland, were bred and housed under conditions of constant temperature and humidity, with sterile bedding and food, according to institutional ethical guidelines. All mice were aged between 8 and 12 weeks.
- DMXAA was synthesized as the sodium salt (Rewcastle et al (1990) Journal of National Cancer Institute 82:528-529). DMXAA sodium salt was dissolved in sterile water and 25 mg/kg in a volume of 0.1 ml per 10 g body weight was injected intraperitoneally (i.p.) into mice.
- Diclofenac (Sigma) was dissolved in dimethylsulphoxide, and was injected i.p. into mice in a volume of 25 μl per 10 g body weight. The required dose of diclofenac was injected concurrently with DMXAA.
- Colon 38 tumour fragments (˜1 mm3) were implanted subcutaneously (s.c.) in the left flank of anaesthetized (sodium pentobarbital, 81 mg/kg) mice. The experiments were initiated when tumours were approximately 3-5 mm in diameter. Tumour-bearing mice were treated with drugs according to the administration schedule described before, and the tumours measured using calipers, three times weekly thereafter. Tumour volumes were calculated as O.52a2b, where a and b are the minor and major axes of the tumour, respectively. The arithmetic means were calculated for each time point, counting cured tumours as zero volume. The growth delay was determined as the difference in the number of days required for the control versus treated tumours to increase four times in volume.
- Mice were treated i.p. with DMXAA or DMXAA combination with diclofenac. At 0.25, 1.5, 3, 4.5 and 6 hours after treatment, the mice were halothane-anaesthetised and the blood was collected through ocular sinus into heparinised plastic microcentrifuge tubes. The animals were then immediately killed by cervical dislocation. Tumour tissues were taken out immediately after mouse being killed, and stored at −70° C. for later DMXAA assay.
- For DMXAA pharmacokinetic studies, the AUC was calculated as a function of time using the log-trapezoidal rule. Cmax was the maximum concentration measured. The half-life (T1/2) was calculated as 0.693/Lz, where Lz is the slope of the terminal linear-portion of the log-concentration-time curve. The relative recoveries and coefficients of variation (CV) for the intra-assay accuracy and precision were 85-115% and 6-10% (n=8 for plasma assay, and n=10 for tumour/liver assay) respectively, over the concentration range of 0.2-100 μM (for DMXAA assay). Inter-assay accuracy was also acceptable with similar relative recoveries (85-115%) and CVs (6-10%, n=8 for plasma assay, and n=10 for tumour/liver assay)
- DMXAA concentrations in plasma and in homogenates of tumour were measured using a specific reverse-phase high-pressure liquid chromatography (HPLC) assay. Automated solid-phase extraction and 2,5-dimethylxanthenone-4-acetic acid (as the internal standard) were used in this assay. Mouse plasma samples were centrifuged (6000 rpm, 5 min) (Biofuge A, Heraeus Christ GmbH, Germany), and then diluted 10-fold with 10 mM ammonium acetate buffer (pH 5.5). Tumour samples were homogenized in 1 ml of 10 mM ammonium acetate buffer (pH 5.5). Thereafter 200 μl of diluted plasma or tumour homogenates were mixed with the internal standard solution (50 μl, 20 μM), and proteins precipitated using ice-cold acetonitrile/methanol (3:1 v/v). After centrifugation (3000 rpm, 10 min, 4° C.), the supernatants were added to ammonium acetate buffer (9 ml) and transferred automatically onto 1 ml/100 mg preconditioned (1 ml acetonitrile/methanol. 3:1 v/v, and 1 ml Milli Q water) C18 Bond-Elut cartridges (Varian, Harbor City, Calif.). This was accomplished using an automated sample preparation with an extraction column system (ASPEC, Gilson Medical, Middleton, Wis.). The cartridges were washed with Milli Q water (1 ml) and the compounds of interest eluted using 1 ml acetonitrile containing 30% methanol.
- The elutes were evaporated to dryness using a centrifugal evaporator (Jouan, St. Nazaire, France) and the residues were dissolved in 200 μl mobile phase. Aliquots (18 μl) were automatically injected into the chromatograph (Waters WISP 712B sample injector and Model 510 pump; Water Associates, Milford, Mass.) with a fluorescence detector (Shimadzu Model RF530; Shimadzu, Kyoto, Japan) with excitation and emission wavelengths set at 345 and 409 nm, respectively, and a LUNA 5μ C18(2) 100×4.6 mm stainless steel column (Phenomenex). Integration and data acquisition were achieved using a Unicam 4880 chromatography data system (Unicam, Cambridge, UK). Compounds were eluted from the column (retention time of DMXAA and internal standard were 8 and 6 minutes, respectively) using a mobile phase of 10 mM ammonium acetate buffer (pH 5.0) and acetonitrile (3:1, v/v) at a flow rate of 1.5 ml/min. Human plasma calibration samples were prepared by adding DMXAA to plasma over the concentration range 0.2-100 μM. Human plasma calibration samples were used. The peak-height ratios of DMXAA to the internal standard were plotted against DMXAA concentration in the calibration standards and the best fit straight line obtained by linear regression analysis. Quantitation of DMXAA in mouse plasma samples was achieved by determining the peak-height ratio in mouse plasma samples and using the equation obtained from the calibration curve.
- The statistical significance of tumour growth inhibition was tested by Students' t-test. Volumes of tumours were calculated using the formula 0.52×minor axis squared×major axis.
- DMXAA (25 mg/kg)+diclofenac (5 mg/kg), a combination which was shown to be non-toxic in toxicity experiments in colon 38 tumour-bearing mice (results not shown), was compared with the DMXAA monotherapy against colon 38 tumours implanted s.c. in mice. The tumour growth delay experiment was conducted using 4 drug regimes: untreated controls, DMXAA alone (25 mg/kg), diclofenac alone (5 mg/kg), and a combination group of DMXAA (25 mg/kg)+diclofenac (5 mg/kg). The results are shown in
FIG. 1 . - Diclofenac alone was found to have no significant effect on the growth of colon 38 tumours. DMXAA produced a growth delay of ˜6 days, but none of the mice were cured. With the combination group, there was a remarkable improvement in the antitumour response in that all the mice were cured (100%). The results showed that coadministration of diclofenac with DMXAA can lead to significant increases in antitumour activity.
- The effect of diclofenac on DMXAA's plasma concentrations was next examined. The 3 hour time point was determined as being the best time point to use because of less variability (Dr Kestell, personal communication). The only combination that gave a significant increase (56%) in DMXAA plasma concentration, was DMXAA (25 mg/kg)+diclofenac (I 00 mg/kg) (Table 1). All the doses of diclofenac below 100 mg/kg had no significant effect on
DMXAA plasma concentrations 3 hours after administration. - An experiment was carried out to determine if diclofenac at 5 mg/kg had any effect on the plasma pharmacokinetics of DMXAA over the first 6 hours. No statistical difference in the DMXAA plasma concentrations were observed with or without coadministered diclofenac (
FIG. 2 ). The AUC values, 1333 μM.hr and 1514 μM.hr, for DMXAA alone and in combination with diclofenac respectively, were also not statistically different. Similarly, the half-life of DMXAA in plasma (2.7 hours) was not statistically different from that obtained with coadministered diclofenac (3.6 hours). These results suggested that the reason for the observed improved antitumour activity with coadministered diclofenac was not as a result of alterations in the plasma pharmacokinetics of DMXAA. - There was no significant difference in the DMXAA concentration in colon 38 tumours following treatment with DMXAA alone or in combination with diclofenac over a five hour time course (
FIG. 3 ). At six hours, however, there was a significant reduction in the DMXAA concentration. The AUC values, 507 μM.hr and 388 μM.hr, of DMXAA monotherapy and combination therapy respectively, showed no significant difference. The Cmax values, 111 μM and 100 μM, of DMXAA monotherapy and combination therapy respectively, similarly showed no significant difference. These results further indicate that the improved anti tumour activity in the presence of diclofenac is not attributable to altered pharmacokinetics of DMXAA. - Diclofenac at high concentrations has been shown in vitro to inhibit glucuronidation (>70%) and 6-methylhydroxylation (>54%) of DMXAA (Zhou et al, Cancer Chemother. Pharmacol., 47: 319-326). In vivo diclofenac (100 mg/kg) is able to increase the plasma concentration and AUC of DMXAA by 24-31% in mice (Zhou et al, Cancer Chemother. Pharmacol., 47: 319-326). Diclofenac (100 mg/kg) increased DMXAA plasma concentration by 56% (Table 5), but lower doses had no significant effect.
- In this study, it had been shown that NSAIDS, in particular diclofenac at 5 mg/kg could enhance DMXAA anti tumour activity (
FIG. 1 ). The growth delay for DMXAA monotherapy was around 6 days with no cure, whereas for DMXAA combination therapy, there was a significant increase in the number of cures. These results suggest that by coadministration of diclofenac, the anti tumour activity of DMXAA can be increased. - The time-course experiments (0-6 hours) of plasma and intratumoral concentrations in both DMXAA monotherapy and combination therapy were conducted (
FIG. 2 andFIG. 3 ). Both of Cmax and AUC values induced by both treatments were similar. In this study, diclofenac was used at 5 mg/kg, a concentration significantly below the effective concentration that can inhibit glucuronidation of DMXAA. These results therefore suggest that the anti tumour activity enhanced by the dose combination of DMXAA (25 mg/kg)+diclofenac (5 mg/kg) was not due to the direct alteration in the pharmacokinetics of DMXAA. - Although there was no significant difference between two therapies in intratumoral AUC values, but there was a significant decrease at the 6 hour time point (
FIG. 3 ), where the intratumoral concentration of DMXAA in the combination group was much lower than the one in the monotherapy. Without being bound by any one theory, it is possible that this might result from diclofenac enhancing DMXAA anti tumour activity by increasing the rate of reduction in tumor blood flow to the tumour, reducing the concentration of DMXAA inside the tumour tissue. - All publications mentioned in this specification are herein incorporated by reference. Various modifications and variations of the described methods and materials of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such embodiments. Indeed various modifications of the described modes for carrying out the invention which are obvious to those skilled in the art are intended to be within the scope of the following claims.
Claims (19)
1-16. (canceled)
17. A pharmaceutical formulation comprising a combination of the compound of formula (I);
or a pharmaceutically acceptable salt or ester thereof and a non-steroidal anti-inflammatory drug (NSAID) compound wherein a unit dose of said pharmaceutical formulation comprises said NSAID compound in an amount which is less than that required to substantially alter the plasma pharmacokinetics of the compound of formula (I) in a subject to be treated,
wherein:
(a) R4 and R5 together with the carbon atoms to which they are joined, form a 6-membered aromatic ring having a substituent —R3 and a radical —(B)—COOH where B is a linear or branched substituted or unsubstituted C1-C6 alkyl radical, which is saturated or ethylenically unsaturated, and wherein R1, R2 and R3 are each independently selected from the group consisting of H, C1-C6, CN, NO2, NH2, OH, OR, NHCOR, NHSO2R, SR, SO2R or NHR, wherein each R is independently C1-C6 alkyl optionally substituted with one or more substituents selected from hydroxy, amino and methoxy; or
(b) one of R4 and R5 is H or a phenyl radical, and the other of R4 and R5 is H or a phenyl radical which may optionally be substituted, thenyl, furyl, naphthyl, a C1-C6 alkyl, cycloalkyl, or aralkyl radical; R1 is H or a C1-C6 alkyl or C1-C6 alkoxy radical; R2 is the radical —(B)—COOH where B is a linear or branched substituted or unsubstituted C1-C6 alkyl radical, which is saturated or ethylenically unsaturated.
18. The pharmaceutical formulation of claim 17 wherein the formulation is adapted for intravenous administration.
19. The pharmaceutical formulation of claim 17 wherein the NSAID compound is diclofenac.
20. The pharmaceutical formulation of claim 17 wherein the compound of formula (I) is 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
21. A process for the preparation of a pharmaceutical formulation which process comprises bringing into association a combination of a compound of formula (I);
or a pharmaceutically acceptable salt or ester thereof, wherein:
(a) R4 and R5 together with the carbon atoms to which they are joined, form a 6-membered aromatic ring having a substituent —R3 and a radical —(B)—COOH where B is a linear or branched substituted or unsubstituted C1-C6 alkyl radical, which is saturated or ethylenically unsaturated, and wherein R1, R2 and R3 are each independently selected from the group consisting of H, C1-C6 alkyl, halogens, NHCOR, NHSO2R, SR, SO2R or NHR, wherein each R is independent C1-C6 alkyl optionally substituted with one or more substituents selected from hydroxy, amino and methoxy; or
(b) one of R4 and R5 is H or a phenyl radical, and the other of R4 and R5 is H or a phenyl radical which may optionally be substituted, thenyl, furyl, naphthyl, a C1-C6 alkyl cycloalkyl, or aralkyl radical; R1 is H or a C1-C6 alkyl or C1-C6 alkoxy radical; R2 is the radical —(B)—COOH where B is a linear or branched substituted or unsubstituted C1-C6 alkyl radical, which is saturated or ethylenically unsaturated.
and a NSAID compound with one or more pharmaceutically acceptable carriers therefor in a unit dose in which said NSAID compound is in an amount which is less than that required to substantially alter the plasma pharmacokinetics of the compound of formula (I) in a subject to be treated.
22. The process according to claim 21 wherein the NSAID compound is diclofenac.
23. The process according to claim 21 or claim 22 wherein the compound of formula (I) is DMXAA.
24. A kit comprising in combination for simultaneous, separate or sequential use in modulating neoplastic growth, a compound of formula (I) as defined in claim 17 or a pharmaceutically acceptable salt or ester thereof and a NSAID compound, wherein said NSAID is provided in a unit dose comprising an amount of NSAID which is less than that required to substantially alter the plasma pharmacokinetics of the compound of formula (I) in a subject to be treated.
25. The kit according to claim 24 wherein the NSAID compound is diclofenac.
26. The kit according to claim 25 wherein the compound of formula (I) is DMXAA.
28. The pharmaceutical formulation of claim 17 wherein the compound of Formula (I) is a compound of Formula (III):
wherein R1, R2 and R3 are each independently selected from the group consisting of H, C1-C6 alkyl, halogen, CF3, CN, NO2, NH2, OH, OR, NHCOR, NHSO2R, SR, SO2R or NHR, wherein each R is independently C1-C6 alkyl optionally substituted with one or more substituents selected from hydroxy, amino and methoxy;
wherein B is as defined for formula (I) in claim 17 ;
and wherein in each of the carbocyclic aromatic rings in formula (I), up to two of the methine (—CH═) groups may be replaced by an aza (—N═) group;
and wherein any two of R1, R2 and R3 may additionally together represent the group —CH═CH—CH═CH—, such that this group, together with the carbon or nitrogen atoms to which it is attached, forms a fused 6 membered aromatic ring.
31. The pharmaceutical formulation of claim 17 wherein R4 is H or a phenyl radical, R5 is H or a phenyl radical which may optionally be substituted, thenyl, furyl, naphthyl, a C1-C6 alkyl, cycloalkyl, or aralkyl radical; R1 is H or a C1-C6 alkyl or C1-C6 alkoxy radical; R2 is radical —(B)—COOH where B is a linear or branched substituted or unsubstituted C1-C6 alkyl radical, which is saturated or ethylenically unsaturated.
32. The pharmaceutical formulation of claim 17 wherein the compound of formula (I) or pharmaceutically acceptable salt or ester thereof and the NSAID are present in a potentiating ratio.
33. The pharmaceutical formulation of claim 17 wherein the ratio of compound of formula (I):NSAID is in the range 10:1 to 1:1.
34. The pharmaceutical formulation of claim 17 wherein the ratio of compound of formula (I):NSAID is about 5:1.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/264,197 US20090062377A1 (en) | 2002-03-22 | 2008-11-03 | Anti-cancer combinations |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0206839A GB2386836B (en) | 2002-03-22 | 2002-03-22 | Anti-cancer combinations |
GB0206839.3 | 2002-03-22 | ||
PCT/GB2003/001320 WO2003080044A1 (en) | 2002-03-22 | 2003-03-20 | Anti-cancer combinations of dmxaa and a nsaid |
US10/946,833 US7462642B2 (en) | 2002-03-22 | 2004-09-22 | Anti-cancer combinations |
US12/264,197 US20090062377A1 (en) | 2002-03-22 | 2008-11-03 | Anti-cancer combinations |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/946,833 Division US7462642B2 (en) | 2002-03-22 | 2004-09-22 | Anti-cancer combinations |
Publications (1)
Publication Number | Publication Date |
---|---|
US20090062377A1 true US20090062377A1 (en) | 2009-03-05 |
Family
ID=9933545
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/946,833 Expired - Fee Related US7462642B2 (en) | 2002-03-22 | 2004-09-22 | Anti-cancer combinations |
US12/264,197 Abandoned US20090062377A1 (en) | 2002-03-22 | 2008-11-03 | Anti-cancer combinations |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/946,833 Expired - Fee Related US7462642B2 (en) | 2002-03-22 | 2004-09-22 | Anti-cancer combinations |
Country Status (6)
Country | Link |
---|---|
US (2) | US7462642B2 (en) |
EP (1) | EP1487433A1 (en) |
JP (1) | JP2005526786A (en) |
AU (1) | AU2003217035A1 (en) |
GB (1) | GB2386836B (en) |
WO (1) | WO2003080044A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011022782A1 (en) * | 2009-08-27 | 2011-03-03 | Medvet Science Pty Ltd | Combinations comprising imatinib mesylate and diclofenac |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000076497A1 (en) * | 1999-06-14 | 2000-12-21 | Cancer Research Ventures Limited | Cancer therapy |
EP1311262A4 (en) | 2000-07-28 | 2005-06-01 | Cancer Rec Tech Ltd | Cancer treatment by combination therapy |
GB0121285D0 (en) | 2001-09-03 | 2001-10-24 | Cancer Res Ventures Ltd | Anti-cancer combinations |
GB2386836B (en) | 2002-03-22 | 2006-07-26 | Cancer Res Ventures Ltd | Anti-cancer combinations |
GB2394658A (en) | 2002-11-01 | 2004-05-05 | Cancer Rec Tech Ltd | Oral anti-cancer composition |
GB0321999D0 (en) * | 2003-09-19 | 2003-10-22 | Cancer Rec Tech Ltd | Anti-cancer combinations |
WO2005077394A1 (en) * | 2004-02-11 | 2005-08-25 | Ramot At Tel-Aviv University Ltd | Compositions for treatment of cancer and inflammation with curcumin and at least one nsaid |
US20100297112A1 (en) * | 2005-08-26 | 2010-11-25 | Antisoma Research Limited | Combinations comprising dmxaa for the treatment of cancer |
CN101437933B (en) | 2005-12-28 | 2013-11-06 | 斯克里普斯研究所 | Natural antisense and non-coding RNA transcripts as drug targets |
KR101770435B1 (en) | 2008-10-03 | 2017-09-05 | 큐알엔에이, 인크. | Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoproteina1 |
US20110294870A1 (en) | 2008-12-04 | 2011-12-01 | Opko Curna, Llc | Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene |
ES2629630T3 (en) | 2008-12-04 | 2017-08-11 | Curna, Inc. | Treatment of diseases related to erythropoietin (EPO) by inhibiting the natural antisense transcript to EPO |
WO2010065671A2 (en) | 2008-12-04 | 2010-06-10 | Curna, Inc. | Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf |
ES2762610T3 (en) | 2009-02-12 | 2020-05-25 | Curna Inc | Treatment of diseases related to brain-derived neurotrophic factor (BDNF) by inhibition of natural antisense transcript for BDNF |
MX2011009751A (en) | 2009-03-16 | 2011-09-29 | Opko Curna Llc | Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2. |
WO2010107740A2 (en) | 2009-03-17 | 2010-09-23 | Curna, Inc. | Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1 |
CN102459596B (en) | 2009-05-06 | 2016-09-07 | 库尔纳公司 | By suppression therapy lipid transfer and the metabolic gene relevant disease of the natural antisense transcript for lipid transfer and metabolic gene |
JP6250930B2 (en) | 2009-05-06 | 2017-12-20 | クルナ・インコーポレーテッド | Treatment of TTP-related diseases by suppression of natural antisense transcripts against tristetraproline (TTP) |
KR101742334B1 (en) | 2009-05-08 | 2017-06-01 | 큐알엔에이, 인크. | Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family |
CN102575251B (en) | 2009-05-18 | 2018-12-04 | 库尔纳公司 | The relevant disease of the reprogramming factor is treated by inhibiting the natural antisense transcript for the reprogramming factor |
KR101703695B1 (en) | 2009-05-22 | 2017-02-08 | 큐알엔에이, 인크. | Treatment of transcription factor e3 (tfe3) and insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to tfe3 |
CN103221541B (en) | 2009-05-28 | 2017-03-01 | 库尔纳公司 | Antiviral gene relevant disease is treated by the natural antisense transcript suppressing antiviral gene |
KR101702689B1 (en) | 2009-06-16 | 2017-02-06 | 큐알엔에이, 인크. | Treatment of paraoxonase 1 (pon1) related diseases by inhibition of natural antisense transcript to pon1 |
WO2010148050A2 (en) | 2009-06-16 | 2010-12-23 | Curna, Inc. | Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene |
CA2765889A1 (en) | 2009-06-24 | 2010-12-29 | Opko Curna, Llc | Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2 |
CA2765815A1 (en) | 2009-06-26 | 2010-12-29 | Opko Curna, Llc | Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene |
CA2768947C (en) | 2009-07-24 | 2018-06-19 | Opko Curna, Llc | Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt) |
US9234199B2 (en) | 2009-08-05 | 2016-01-12 | Curna, Inc. | Treatment of insulin gene (INS) related diseases by inhibition of natural antisense transcript to an insulin gene (INS) |
EP2464731B1 (en) | 2009-08-11 | 2016-10-05 | CuRNA, Inc. | Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq) |
WO2011022606A2 (en) | 2009-08-21 | 2011-02-24 | Curna, Inc. | Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip |
CN102482671B (en) | 2009-08-25 | 2017-12-01 | 库尔纳公司 | IQGAP relevant diseases are treated by suppressing the natural antisense transcript of ' gtpase activating protein containing IQ die bodys ' (IQGAP) |
EP2480669B1 (en) | 2009-09-25 | 2017-11-08 | CuRNA, Inc. | Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity |
ES2661813T3 (en) | 2009-12-16 | 2018-04-04 | Curna, Inc. | Treatment of diseases related to membrane transcription factor peptidase, site 1 (mbtps1) by inhibition of the natural antisense transcript to the mbtps1 gene |
CA2782373C (en) | 2009-12-23 | 2019-03-26 | Opko Curna, Llc | Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf |
US9068183B2 (en) | 2009-12-23 | 2015-06-30 | Curna, Inc. | Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2 |
WO2011090740A2 (en) | 2009-12-29 | 2011-07-28 | Opko Curna, Llc | Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1 |
ES2585829T3 (en) | 2009-12-29 | 2016-10-10 | Curna, Inc. | Treatment of diseases related to tumor protein 63 (p63) by inhibition of natural antisense transcription to p63 |
US20120289583A1 (en) | 2009-12-31 | 2012-11-15 | Curna, Inc. | Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3) |
KR101878501B1 (en) | 2010-01-04 | 2018-08-07 | 큐알엔에이, 인크. | Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8 |
EP2521785B1 (en) | 2010-01-06 | 2022-03-09 | CuRNA, Inc. | Inhibition of natural antisense transcript to a pancreatic developmental gene for use in a treatment of pancreatic developmental gene related diseases |
DK2524039T3 (en) | 2010-01-11 | 2018-03-12 | Curna Inc | TREATMENT OF GENDER HORMON-BINDING GLOBULIN (SHBG) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTS TO SHBG |
CN102782135A (en) | 2010-01-25 | 2012-11-14 | 库尔纳公司 | Treatment of RNase H1 related diseases by inhibition of natural antisense transcript to RNase H1 |
CN102844435B (en) | 2010-02-22 | 2017-05-10 | 库尔纳公司 | Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1 |
ES2657969T3 (en) | 2010-04-02 | 2018-03-07 | Curna, Inc. | Treatment of diseases related to Colony Stimulating Factor 3 (CSF3) by inhibition of the natural antisense transcript to CSF3 |
RU2610661C2 (en) | 2010-04-09 | 2017-02-14 | Курна, Инк. | Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21 |
CN107988228B (en) | 2010-05-03 | 2022-01-25 | 库尔纳公司 | Treatment of Sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to Sirtuin (SIRT) |
TWI531370B (en) | 2010-05-14 | 2016-05-01 | 可娜公司 | Treatment of par4 related diseases by inhibition of natural antisense transcript to par4 |
US8895528B2 (en) | 2010-05-26 | 2014-11-25 | Curna, Inc. | Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1 |
CA2799596C (en) | 2010-05-26 | 2020-09-22 | Curna, Inc. | Treatment of methionine sulfoxide reductase a (msra) related diseases by inhibition of natural antisense transcript to msra |
KR102008708B1 (en) | 2010-06-23 | 2019-08-08 | 큐알엔에이, 인크. | Treatment of sodium channel voltage-gated, alpha subunit (scna) related diseases by inhibition of natural abtisense transcript to scna |
CN103068982B (en) | 2010-07-14 | 2017-06-09 | 库尔纳公司 | DLG relevant diseases are treated by suppressing the natural antisense transcript of the big homologue of plate-like (DLG) |
EP2625274B1 (en) | 2010-10-06 | 2017-07-19 | CuRNA, Inc. | Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4 |
CA2815212A1 (en) | 2010-10-22 | 2012-04-26 | Curna, Inc. | Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua |
WO2012068340A2 (en) | 2010-11-18 | 2012-05-24 | Opko Curna Llc | Antagonat compositions and methods of use |
CN103459599B (en) | 2010-11-23 | 2017-06-16 | 库尔纳公司 | NANOG relevant diseases are treated by suppressing the natural antisense transcript of NANOG |
WO2012167028A2 (en) * | 2011-06-02 | 2012-12-06 | The Regents Of The University Of California | Compositions and methods for treating cancer and diseases and conditions responsive to cell growth inhibition |
JP6188686B2 (en) | 2011-06-09 | 2017-08-30 | カッパーアールエヌエー,インコーポレイテッド | Treatment of FXN-related diseases by inhibition of natural antisense transcripts to frataxin (FXN) |
CA2847811C (en) | 2011-09-06 | 2019-10-22 | Curna, Inc. | Treatment of diseases related to alpha subunits of sodium channels, voltage-gated (scnxa) with small molecules |
ES2611086T3 (en) * | 2011-12-20 | 2017-05-04 | Ectin Research Ab | Synergistic combination for tumor inhibition |
US20150031750A1 (en) | 2012-03-15 | 2015-01-29 | The Scripps Research Institute | Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf |
JP7156154B2 (en) * | 2019-04-18 | 2022-10-19 | 株式会社島津製作所 | Medium processing system and medium processing method |
Citations (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3678077A (en) * | 1969-03-29 | 1972-07-18 | Michio Nakanishi | 9-oxoxanthen-2-yl-alkanoic acids |
US4602034A (en) * | 1981-11-25 | 1986-07-22 | Lipha, Lyonnaise Industrielle Pharmaceutique | (Oxo-4-4H-(1)-benzopyran-8-yl) alkanoic acids, salts and derivatives, their manufacture and medicines containing them |
US4704355A (en) * | 1985-03-27 | 1987-11-03 | New Horizons Diagnostics Corporation | Assay utilizing ATP encapsulated within liposome particles |
US5126129A (en) * | 1988-05-23 | 1992-06-30 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services | Cancer therapy using interleukin-2 and flavone compounds |
US5281620A (en) * | 1986-12-23 | 1994-01-25 | Cancer Research Campaign Technology Limited | Compounds having antitumor and antibacterial properties |
US5464826A (en) * | 1984-12-04 | 1995-11-07 | Eli Lilly And Company | Method of treating tumors in mammals with 2',2'-difluoronucleosides |
US5620875A (en) * | 1995-02-17 | 1997-04-15 | University Of Portland | Transfer of taxol from yew tree cuttings into a culture medium over time |
US5817684A (en) * | 1996-12-13 | 1998-10-06 | Eli Lilly And Company | Leukotriene antagonists for use in the treatment or inhibition of cerebral focal stroke |
US5863904A (en) * | 1995-09-26 | 1999-01-26 | The University Of Michigan | Methods for treating cancers and restenosis with P21 |
US5910505A (en) * | 1997-03-21 | 1999-06-08 | Eli Lilly And Company | Leukotriene antagonists for use in the treatment or inhibition of oral squamous cell carcinoma |
US6174873B1 (en) * | 1998-11-04 | 2001-01-16 | Supergen, Inc. | Oral administration of adenosine analogs |
US6194454B1 (en) * | 1999-03-01 | 2001-02-27 | Pfizer Inc. | Cyano containing oxamic acids and derivatives as thyroid receptor ligands |
US20010041713A1 (en) * | 2000-02-17 | 2001-11-15 | Joanne Waldstreicher | Treatment or prevention of prostate cancer with a COX-2 selective inhibiting drug |
US20030003092A1 (en) * | 1999-06-14 | 2003-01-02 | Krissansen Geoffrey W. | Cancer therapy |
US6667337B2 (en) * | 2000-03-03 | 2003-12-23 | Cancer Research Technology Limited | Combination therapy for cancer |
US20040087611A1 (en) * | 2000-07-28 | 2004-05-06 | Baguley Bruce Charles | Cancer treatment by combination therapy |
US20040204480A1 (en) * | 2001-09-03 | 2004-10-14 | Cancer Research Technology Limited | Anti-cancer combinations |
US6806257B1 (en) * | 1999-10-20 | 2004-10-19 | Board Of Trustees Of Southern Illinois University | Flavones as inducible nitric oxide synthase inhibitors, cyclooxygenase-2 inhibitors and potassium channel activators |
US20050131059A1 (en) * | 2002-03-22 | 2005-06-16 | Cancer Research Technology Limited | Anti-cancer combinations |
US20060009505A1 (en) * | 2002-11-01 | 2006-01-12 | Cancer Research Technology Limited | Anti-cancer composition comprising DMXAA or related compound |
US20070082937A1 (en) * | 2003-09-19 | 2007-04-12 | Cancer Research Technology Limited | Anti cancer combinations comprising a cox-2 inhibitor |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2015265A1 (en) | 1969-03-29 | 1970-10-08 | Yoshitomi Pharmaceutical Industries Ltd., Osaka (Japan) | Arylalkanoic acids and processes for their preparation |
ATE102616T1 (en) | 1986-12-23 | 1994-03-15 | Warner Lambert Co | COMPOUNDS WITH ANTITUMORAL AND ANTIBACTERIAL PROPERTIES. |
JPH01193227A (en) | 1988-01-29 | 1989-08-03 | Res Dev Corp Of Japan | Adjuvant for cancer immunotherapy |
US5075287A (en) | 1989-03-03 | 1991-12-24 | Nisshin Oil Mills, Inc. | Muramyl peptide derivatives and immunoregulating compositions containing them |
CA2025907A1 (en) | 1989-09-21 | 1991-03-22 | Franklin D. Collins | Method of transporting compositions across the blood brain barrier |
US5250296A (en) | 1990-11-29 | 1993-10-05 | Takeda Chemical Industries, Ltd. | Immunostimulant agent containing interleukin-2 and 5'-deoxy-5-fluorouridine |
EP0551200A1 (en) | 1992-01-07 | 1993-07-14 | National University Of Singapore | Protein phosphatase inhibitors for use in therapy |
CA2086874E (en) | 1992-08-03 | 2000-01-04 | Renzo Mauro Canetta | Methods for administration of taxol |
GB9308166D0 (en) | 1993-04-20 | 1993-06-02 | Cancer Res Campaign Tech | Cancer therapy |
GB9320484D0 (en) | 1993-10-05 | 1993-11-24 | Wellcome Found | Pharmaceutical combinations |
WO1996032418A1 (en) | 1995-04-13 | 1996-10-17 | Laboratoires Om S.A. | Anti-cd14 antibodies for use in the induction of il-10 secretion |
AU5857296A (en) | 1995-05-17 | 1996-11-29 | Eli Lilly And Company | Use of leukotriene antagonists for alzheimer's disease |
JPH0940690A (en) | 1995-05-23 | 1997-02-10 | Yutaka Sashita | Steroid glycoside and medicine containing the same as active ingredient |
WO1997004761A1 (en) | 1995-07-28 | 1997-02-13 | Trustees Of Boston University | Methods and compositions for treating cell proliferative disorders |
US5977077A (en) | 1995-08-28 | 1999-11-02 | Interlab Corporation | Xanthone analogs for the treatment of infectious diseases |
WO1998025600A1 (en) | 1996-12-13 | 1998-06-18 | Eli Lilly And Company | Leukotriene antagonists for treatment or inhibition of gout |
UA47505C2 (en) | 1996-12-13 | 2002-07-15 | Елі Ліллі Енд Компані | A method for treatment a flat-cell cancer of mouth cavity by means of leicotrien antagonists |
US5914340A (en) | 1997-03-21 | 1999-06-22 | Eli Lilly And Company | Leukotriene antagonists useful for treating dermatoses |
US5998454A (en) | 1997-03-21 | 1999-12-07 | Eli Lilly And Company | Leukotriene antagonists useful for treating iritis |
WO1998042336A1 (en) | 1997-03-21 | 1998-10-01 | Eli Lilly And Company | Leukotriene antagonists useful for treating gingivitis |
WO1998042345A1 (en) | 1997-03-21 | 1998-10-01 | Eli Lilly And Company | Leukotriene antagonists useful for treating cerebral focal stroke |
AU6764798A (en) | 1997-03-21 | 1998-10-20 | Eli Lilly And Company | Leukotriene antagonists useful for treating cystic fibrosis |
AU6450498A (en) | 1997-03-21 | 1998-10-20 | Eli Lilly And Company | Leukotriene antagonists useful for treating gout |
AU6572298A (en) | 1997-03-21 | 1998-10-20 | Eli Lilly And Company | Leukotriene antagonists useful for treating ischemia reperfusion injury |
DE19721211A1 (en) | 1997-05-21 | 1998-11-26 | Lindner Sen Wolfgang Dr Med | Three-fold treatment of tumours providing synergistic effect |
EP1107784A2 (en) | 1998-08-24 | 2001-06-20 | Maxim Pharmaceuticals, Inc. | Activation and protection of t-cells (cd4?+ and cd8?+ ) using an h 2? receptor agonist and other t-cell activating agents |
AUPP609198A0 (en) | 1998-09-22 | 1998-10-15 | Curtin University Of Technology | Use of non-peptidyl compounds for the treatment of insulin related ailments |
GB9903404D0 (en) | 1999-02-16 | 1999-04-07 | Angiogene Pharm Ltd | Methods of treatment and compositions useful for the treatment of diseases involving angiogenesis |
JP2003513914A (en) | 1999-11-11 | 2003-04-15 | イーライ・リリー・アンド・カンパニー | Oncolytic drug combinations for the treatment of cancer |
AU1916501A (en) | 1999-11-11 | 2001-06-06 | Eli Lilly And Company | Oncolytic combinations for the treatment of cancer |
WO2001034198A2 (en) | 1999-11-11 | 2001-05-17 | Eli Lilly And Company | Oncolytic combinations for the treatment of cancer |
CZ20021551A3 (en) | 1999-11-11 | 2003-02-12 | Eli Lilly And Company | Oncolytic combinations for treating cancer |
US20100297112A1 (en) | 2005-08-26 | 2010-11-25 | Antisoma Research Limited | Combinations comprising dmxaa for the treatment of cancer |
GB0517387D0 (en) | 2005-08-26 | 2005-10-05 | Antisoma Res Ltd | Combinations for the treatment of cancer |
-
2002
- 2002-03-22 GB GB0206839A patent/GB2386836B/en not_active Expired - Fee Related
-
2003
- 2003-03-20 JP JP2003577872A patent/JP2005526786A/en active Pending
- 2003-03-20 AU AU2003217035A patent/AU2003217035A1/en not_active Abandoned
- 2003-03-20 EP EP03712423A patent/EP1487433A1/en not_active Withdrawn
- 2003-03-20 WO PCT/GB2003/001320 patent/WO2003080044A1/en active Application Filing
-
2004
- 2004-09-22 US US10/946,833 patent/US7462642B2/en not_active Expired - Fee Related
-
2008
- 2008-11-03 US US12/264,197 patent/US20090062377A1/en not_active Abandoned
Patent Citations (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3678077A (en) * | 1969-03-29 | 1972-07-18 | Michio Nakanishi | 9-oxoxanthen-2-yl-alkanoic acids |
US4602034A (en) * | 1981-11-25 | 1986-07-22 | Lipha, Lyonnaise Industrielle Pharmaceutique | (Oxo-4-4H-(1)-benzopyran-8-yl) alkanoic acids, salts and derivatives, their manufacture and medicines containing them |
US5464826A (en) * | 1984-12-04 | 1995-11-07 | Eli Lilly And Company | Method of treating tumors in mammals with 2',2'-difluoronucleosides |
US4704355A (en) * | 1985-03-27 | 1987-11-03 | New Horizons Diagnostics Corporation | Assay utilizing ATP encapsulated within liposome particles |
US5281620A (en) * | 1986-12-23 | 1994-01-25 | Cancer Research Campaign Technology Limited | Compounds having antitumor and antibacterial properties |
US5126129A (en) * | 1988-05-23 | 1992-06-30 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services | Cancer therapy using interleukin-2 and flavone compounds |
US5620875A (en) * | 1995-02-17 | 1997-04-15 | University Of Portland | Transfer of taxol from yew tree cuttings into a culture medium over time |
US5863904A (en) * | 1995-09-26 | 1999-01-26 | The University Of Michigan | Methods for treating cancers and restenosis with P21 |
US5817684A (en) * | 1996-12-13 | 1998-10-06 | Eli Lilly And Company | Leukotriene antagonists for use in the treatment or inhibition of cerebral focal stroke |
US5910505A (en) * | 1997-03-21 | 1999-06-08 | Eli Lilly And Company | Leukotriene antagonists for use in the treatment or inhibition of oral squamous cell carcinoma |
US6174873B1 (en) * | 1998-11-04 | 2001-01-16 | Supergen, Inc. | Oral administration of adenosine analogs |
US6194454B1 (en) * | 1999-03-01 | 2001-02-27 | Pfizer Inc. | Cyano containing oxamic acids and derivatives as thyroid receptor ligands |
US20030003092A1 (en) * | 1999-06-14 | 2003-01-02 | Krissansen Geoffrey W. | Cancer therapy |
US6806257B1 (en) * | 1999-10-20 | 2004-10-19 | Board Of Trustees Of Southern Illinois University | Flavones as inducible nitric oxide synthase inhibitors, cyclooxygenase-2 inhibitors and potassium channel activators |
US20010041713A1 (en) * | 2000-02-17 | 2001-11-15 | Joanne Waldstreicher | Treatment or prevention of prostate cancer with a COX-2 selective inhibiting drug |
US6667337B2 (en) * | 2000-03-03 | 2003-12-23 | Cancer Research Technology Limited | Combination therapy for cancer |
US20040087611A1 (en) * | 2000-07-28 | 2004-05-06 | Baguley Bruce Charles | Cancer treatment by combination therapy |
US20040204480A1 (en) * | 2001-09-03 | 2004-10-14 | Cancer Research Technology Limited | Anti-cancer combinations |
US20070060637A1 (en) * | 2001-09-03 | 2007-03-15 | Cancer Research Technology Limited | Anti-cancer combinations |
US20080070849A1 (en) * | 2001-09-03 | 2008-03-20 | Cancer Research Technology Limited | Anti-cancer combinations |
US20080070847A1 (en) * | 2001-09-03 | 2008-03-20 | Cancer Research Technology Limited | Anti-cancer combinations |
US20080070848A1 (en) * | 2001-09-03 | 2008-03-20 | Cancer Research Technology Limited | Anti-cancer combinations |
US20080070886A1 (en) * | 2001-09-03 | 2008-03-20 | Cancer Research Technology Limited | Anti-cancer combinations |
US20050131059A1 (en) * | 2002-03-22 | 2005-06-16 | Cancer Research Technology Limited | Anti-cancer combinations |
US7462642B2 (en) * | 2002-03-22 | 2008-12-09 | Cancer Research Technology Limited | Anti-cancer combinations |
US20060009505A1 (en) * | 2002-11-01 | 2006-01-12 | Cancer Research Technology Limited | Anti-cancer composition comprising DMXAA or related compound |
US20070082937A1 (en) * | 2003-09-19 | 2007-04-12 | Cancer Research Technology Limited | Anti cancer combinations comprising a cox-2 inhibitor |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011022782A1 (en) * | 2009-08-27 | 2011-03-03 | Medvet Science Pty Ltd | Combinations comprising imatinib mesylate and diclofenac |
Also Published As
Publication number | Publication date |
---|---|
US20050131059A1 (en) | 2005-06-16 |
JP2005526786A (en) | 2005-09-08 |
GB2386836A (en) | 2003-10-01 |
US7462642B2 (en) | 2008-12-09 |
WO2003080044A1 (en) | 2003-10-02 |
GB2386836B (en) | 2006-07-26 |
AU2003217035A1 (en) | 2003-10-08 |
EP1487433A1 (en) | 2004-12-22 |
GB0206839D0 (en) | 2002-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7462642B2 (en) | Anti-cancer combinations | |
US6573290B1 (en) | DFMO and celecoxib in combination for cancer chemoprevention and therapy | |
US20070060637A1 (en) | Anti-cancer combinations | |
US7189752B2 (en) | Use of etodolac for the treatment of chronic lymphocytic leukemia | |
US8278349B2 (en) | Cancer treatment using FTS and 2-deoxyglucose | |
Tilaoui et al. | Differential effect of artemisinin against cancer cell lines | |
US10729669B2 (en) | Compositions and methods for treating cancer | |
US7105560B1 (en) | Use of etodolac in the treatment of multiple myeloma | |
US11013711B2 (en) | Fatty acid esters of hydroxy fatty acids (FAHFAs) for use in the treatment of type 1 diabetes | |
CN1543356B (en) | Anti-tumor agent | |
US20030170299A1 (en) | Therapeutic methods for acute myeloid leukemia | |
US9463198B2 (en) | Compositions and methods for reducing or preventing metastasis | |
US11426385B2 (en) | Methods of improving cancer chemotherapy | |
KR20080047402A (en) | Combinations comprising dmxaa for the treatment of cancer | |
KR20080034151A (en) | Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer | |
WO2001034134A2 (en) | Oncolytic combinations for the treatment of cancer | |
KR20200039756A (en) | MEK / PI3K, JAK / MEK, JAK / PI3K / mTOR and MEK / PI3K / mTOR inhibitors of biological pathways and methods to improve lymph uptake, bioavailability and solubility of therapeutic compounds | |
CN101309681A (en) | Combinations comprising dmxaa for the treatment of cancer | |
KR20080030659A (en) | Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: CANCER RESEARCH TECHNOLOGY LIMITED,UNITED KINGDOM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WANG, LIANG-CHUAN STEVE;PAXTON, JAMES WILLIAM;CHING, LAI-MING;AND OTHERS;SIGNING DATES FROM 20050113 TO 20050126;REEL/FRAME:024257/0352 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |